Home Categories API Isonicotinic acid hydrazide
A4982812

Isonicotinic acid hydrazide , 98% , 54-85-3

Synonym(s):
Isoniazid;INH;Isonicotinic acid hydrazide;Isonicotinic hydrazide;Isoniazide, 4-Pyridinecarbohydrazide, Isonicotinic acid hydrazide

CAS NO.:54-85-3

Empirical Formula: C6H7N3O

Molecular Weight: 137.14

MDL number: MFCD00006426

EINECS: 200-214-6

Pack Size Price Stock Quantity
25G RMB31.20 In Stock
50g RMB63.20 In Stock
100G RMB84.80 In Stock
250g RMB215.20 In Stock
500G RMB299.20 In Stock
2.5KG RMB1227.20 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 171-173 °C (lit.)
Boiling point: 251.97°C (rough estimate)
Density  1.2620 (rough estimate)
refractive index  1.6910 (estimate)
Flash point: >250°C
storage temp.  2-8°C
solubility  125g/l
form  Crystals or Crystalline Powder
pka pKa 2.00/3.60/10.8(H2O) (Uncertain)
color  White or colorless
Odor Odorless
PH Range 5.5 - 6.5 at 10 g/l at 25 °C
PH 6-8 (50g/l, H2O, 20℃)
Water Solubility  14 g/100 mL (25 ºC)
Sensitive  Air Sensitive
Merck  14,5186
BRN  119374
BCS Class 1,3
Stability: Stability Stable, but may be air or light sensitive. Combustible. Incompatible with strong oxidizing agents, chloral, aldehydes, iodine, ferric salts, hypochlorites.
InChIKey QRXWMOHMRWLFEY-UHFFFAOYSA-N

Description and Uses

Isoniazid, the hydrazide of isonicotinic acid was introduced into medical practice for treating tuberculosis in 1953. Isoniazid exhibits bactericidal action on Mycobacterium tuberculosis. It inhibits the synthesis of mycolic acid, an important component of the cell membrane of mycobacteria. Mycolic acid is specific only to mycobacteria, and it is the cause of the selective toxicity of the drug with respect to these microorganisms.
Mutants that are resistant to isoniazid are rarely seen in nature, and in a spontaneously growing population of tuberculous bacillus there is approximately one mutant in every 105 –106 organisms. Large populations of microorganisms of the order 109 –1010 bacilli in the pulmonary cavities contain a significant number of resistant mutants. If only isoniazid is taken during treatment, an increased number of mutants will be observed and they will eventually become the dominant phenotype. The transformation from sensitive to nonsensitive microorganisms during treatment is called secondary or acquired resistance, which can originate over the course of a few weeks. Isoniazid is the most important drug for treating pulmonary and nonpulmonary forms of tuberculosis. It is active against both intracellular and extracellular organisms. In order to prevent secondary resistance, isoniazid should be used with other effective drugs (usually rifampin). Synonyms of this drug are tubazid, andrazide, niazid, piridizin, and many others.

Isoniazid is an antimicrobial used for the prevention of tuberculosis infection or used concurrently with another agent for the treatment of tuberculosis infection. Rifampin, pyrazinamide, or both of these agents are commonly used with isoniazid. Isoniazid is the only Food and Drug Administration approved drug to treat latent tuberculosis in order to prevent it from becoming active.

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315
Precautionary statements  P264-P270-P280-P301+P312-P302+P352-P332+P313
Hazard Codes  Xn
Risk Statements  22-38-40-36/37/38
Safety Statements  37-36/37/39-26
RIDADR  2811
WGK Germany  3
RTECS  NS1751850
TSCA  Yes
PackingGroup  III
HS Code  29333999
Toxicity LD50 in mice (mg/kg): 151 i.p., 149 i.v. (Jenney, Pfeiffer)

RELATED PRODUCTS